Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

Trial Profile

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AG-019 (Primary) ; Teplizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors ActoBio Therapeutics
  • Most Recent Events

    • 08 Aug 2019 According to an Intrexon Corporation media release, company has initiated enrollment of the next two patient cohorts of the study
    • 01 Jul 2019 According to an ActoBio Therapeutics media release, in the next stage of this study, AG019 will be utilized in combination with PRV-031 pursuant to a collaboration with Provention Bio. Inc.The company is looking forward to collaborating with Provention Bio in this next stage of testing in patients.
    • 01 Jul 2019 According to an ActoBio Therapeutics media release, the results of this current trial are expected in 2020 and will provide initial data regarding the safety and efficacy of AG019 in humans.The company look forward to learning more about the combination of PRV-031 plus AG019 as this study advances.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top